2023 Scientific Sessions

LB-5
Long-term Outcomes following Large-Bore Thrombectomy with the FlowTriever System for the Treatment of Pulmonary Embolism from the Full 800-Patient US Cohort of the FLASH Registry

Presenter

Sameer J. Khandhar, M.D., FSCAI, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Catalin Toma, M.D., University of Pittsburgh Medical Center, Pittsburgh, PA and Sameer J. Khandhar, M.D., FSCAI, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

Keywords: Pulmonary Embolism (PE)

Background


There is growing data showing safety and effectiveness of large-bore thrombectomy for the treatment of pulmonary embolism (PE), but limited data exist on long-term outcomes. Final 6-month results are reported from the US cohort of the FLASH registry for mechanical thrombectomy in PE.

Methods


FLASH is a prospective, single-arm, multicenter registry of acute PE patients treated with the FlowTriever System (Inari Medical). Six-month clinical outcomes were assessed, including mMRC dyspnea score, right ventricular (RV) function, 6-minute walk test (6MWT) distances, and PEmb Quality of Life (QoL) scores.

Results


Of the 800 patients enrolled across 50 US sites, 54.1% were male and mean age was 61.2 years. Thrombolytic contraindications were reported in 32.1% of patients, and 77.1% were classified as intermediate-high-risk and 8.0% as high-risk. Most patients (74.8%) completed all study visits through 6-month follow-up.

Previously reported acute outcomes included intraprocedural reduction in mean pulmonary artery pressure of 7.6±6.3 mmHg and a 48-hr major adverse event rate of 1.8%. All-cause mortality was 0.3% at the 48-hr visit, 0.8% at the 30-day visit, and 4.6% at study exit (median = 199 days post-treatment). Median mMRC dyspnea score improved from 3.0 at baseline to 0.0 at 6 months (P <0.0001). The % of patients with normal RV function on echocardiography increased from 15.1% at baseline to 95.1% at 6 months (P <0.0001), and the % of patients with RV systolic pressure ≤40mm Hg improved from 28.4% at baseline to 93.9% at 6 months. Median 6-MWT distances increased from 180 m at 48 hr to 398 m at 6 months (P <0.0001). Median PEmb QoL Frequency of Complaints scores improved from 12.5 at 48 hr to 1.6 at 6 months (P <0.0001). Six-month prevalence of site-reported chronic thromboembolic pulmonary hypertension was 1.0% and chronic thromboembolic disease was 1.9%.

Conclusions


Long-term mortality was low following treatment with the FlowTriever System, and significant improvements in patient symptoms, cardiac function, and quality of life were observed at 6 months. These data suggest that rapid extraction of thrombus may prevent long-term sequelae in PE patients, though comparative data relative to conservative management are needed.